Literature DB >> 31099654

CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice.

Amy E DeZern1, Luca Malcovati2, Benjamin L Ebert3.   

Abstract

Unexplained blood cytopenias can be a clinical challenge for patients and clinicians alike. The relationship between these cytopenias and myeloid neoplasms like myelodysplastic syndromes (MDS) is currently an area of active research. There have been marked developments in our understanding of clonal hematopoiesis based on findings of somatic mutations in genes known to be associated with MDS. This has led to newer terms to describe precursor states to MDS, such as clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS). These conditions may allow earlier diagnosis, modify surveillance for MDS, and guide additional therapies. This review summarizes recent updates in the field for affected patients.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31099654     DOI: 10.1200/EDBK_239083

Source DB:  PubMed          Journal:  Am Soc Clin Oncol Educ Book        ISSN: 1548-8748


  14 in total

Review 1.  Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states.

Authors:  Lukasz P Gondek; Amy E DeZern
Journal:  Lancet Haematol       Date:  2019-12-03       Impact factor: 18.959

Review 2.  CHIP: is clonal hematopoiesis a surrogate for aging and other disease?

Authors:  Lukasz P Gondek
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 3.  Clonal hematopoiesis and bone marrow failure syndromes.

Authors:  Sergiu Pasca; Lukasz P Gondek
Journal:  Best Pract Res Clin Haematol       Date:  2021-05-25       Impact factor: 3.670

Review 4.  Clonal Hematopoiesis: Role in Hematologic and Non-Hematologic Malignancies.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-09-01       Impact factor: 3.122

5.  Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms.

Authors:  Mithun Vinod Shah; Abhishek A Mangaonkar; Kebede H Begna; Hassan B Alkhateeb; Patricia Greipp; Ahmad Nanaa; Michelle A Elliott; William J Hogan; Mark R Litzow; Kristen McCullough; Ayalew Tefferi; Naseema Gangat; Mrinal M Patnaik; Aref Al-Kali; Rong He; Dong Chen
Journal:  Blood Cancer J       Date:  2022-07-08       Impact factor: 9.812

Review 6.  Clonal hematopoiesis in cancer.

Authors:  Soo J Park; Rafael Bejar
Journal:  Exp Hematol       Date:  2020-02-07       Impact factor: 3.084

Review 7.  Redistribution, homing and organ-invasion of neoplastic stem cells in myeloid neoplasms.

Authors:  Peter Valent; Irina Sadovnik; Gregor Eisenwort; Harald Herrmann; Karin Bauer; Niklas Mueller; Wolfgang R Sperr; Daniel Wicklein; Udo Schumacher
Journal:  Semin Cancer Biol       Date:  2019-08-10       Impact factor: 15.707

8.  Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNγ signaling.

Authors:  Daniel Hormaechea-Agulla; Katie A Matatall; Duy T Le; Bailee Kain; Xiaochen Long; Pawel Kus; Roman Jaksik; Grant A Challen; Marek Kimmel; Katherine Y King
Journal:  Cell Stem Cell       Date:  2021-03-19       Impact factor: 25.269

Review 9.  Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders.

Authors:  Alejandro Ferrer; Abhishek A Mangaonkar; Mrinal M Patnaik
Journal:  Curr Hematol Malig Rep       Date:  2022-05-07       Impact factor: 4.213

Review 10.  Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS.

Authors:  Jennifer J Trowbridge; Daniel T Starczynowski
Journal:  J Exp Med       Date:  2021-06-15       Impact factor: 17.579

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.